EMA Authorised: Jayempi (azathioprine) — Lipomed GmbH

View source ↗

Summary

The EMA authorised Jayempi (azathioprine) by Lipomed GmbH for preventing graft rejection in organ transplant patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Rejection

Drugs mentioned

• Jayempi (azathioprine)

Snippet

Status: Authorised. Therapeutic area: Graft Rejection. MAH: Lipomed GmbH. Decision date: 13/04/2026